Browse > Article
http://dx.doi.org/10.3857/jkstro.2011.29.1.36

Radiation Therapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis  

Park, Seung-Gyu (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University)
Kim, Jin-Hee (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University)
Byun, Sang-Jun (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University)
Kim, Ok-Bae (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University)
Hwang, Jae-Seok (Department of Internal Medicine, Dongsan Medical Center, Keimyung University)
Oh, Young-Kee (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University)
Choi, Tae-Jin (Department of Medical Engineering, Dongsan Medical Center, Keimyung University School of Medicine)
Publication Information
Radiation Oncology Journal / v.29, no.1, 2011 , pp. 36-43 More about this Journal
Abstract
Purpose: To evaluate the effectiveness of radiation therapy (RT) for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) and to analyze the prognostic factors. Materials and Methods: From December 2004 to April 2009, 70 patients who had HCC with PVTT were treated with RT at Keimyung University Dongsan Medical Center. Nineteen patients whose total dose was below 30 Gy and one patient who underwent liver transplantation were excluded. The remaining 50 patients (45 males, 5 females; median age 55 years) were analyzed. According to the LCSGJ TNM stage, there were 27 patients (54.0%) with stage III and 23 (46.0%) with stage IV. Total dose of 30~54 Gy was administered (median 45). Thirty patients (60.0%) were treated with concurrent chemoradiation therapy (CCRT). The median follow-up duration was from 13.5 months (range, 3 to 70 months). Results: The median survival time from the start of RT was 9 months. One-year and 2-year overall survival rates were 24.9% and 11.2%, respectively. At the follow-up time, three patients (6.0%) displayed no evidence of disease. Seven patients (14.0%) were alive with disease, and 40 (80.0%) patients had expired due to disease progression. CCRT was associated with worse survival than RT alone (p=0.034), Response to RT (p=0.037), CLIP stage (p=0.017), and TNM stage (p=0.041) were statistically significant prognostic factors. There was no radiation-induced liver disease. Conclusion: RT is an effective and safe modality for HCC with PVTT. Further studies such as prospective randomized trials are needed to confirm the role of RT for HCC with PVTT.
Keywords
Hepatocellular carcinoma; Portal vein; Radiotherapy; Concurrent chemoradiotherapy;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004;101:796-802   DOI   ScienceOn
2 Mornex F, Girard N, Beziat C, et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006;66:1152-1158   DOI   ScienceOn
3 Xu ZY, Liang SX, Zhu J, et al. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 2006;65:189-195   DOI   ScienceOn
4 Shim SJ, Seong J, Lee IJ, Han KH, Chon CY, Ahn SH. Radiation-induced hepatic toxicity after radiotherapy combined with chemotherapy for hepatocellular carcinoma. Hepatol Res 2007;37:906-913   DOI   ScienceOn
5 Leung TW, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001;28:514-520   DOI   ScienceOn
6 Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000;31:840-845   DOI   ScienceOn
7 Ikai I, Takayasu K, Omata M, et al. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol 2006;41:884-892   DOI   ScienceOn
8 Seong J, Shim SJ, Lee IJ, Han KH, Chon CY, Ahn SH. Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:1037-1042   DOI   ScienceOn
9 Lee IJ, Seong J, Shim SJ, Han KH. Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy. Int J Radiat Oncol Biol Phys 2009;73:154-158   DOI   ScienceOn
10 Robertson JM, Lawrence TS, Dworzanin LM, et al. Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy. J Clin Oncol 1993;11:1286-1293   DOI
11 Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225-235   DOI   ScienceOn
12 Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236   DOI   ScienceOn
13 Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27:1800-1805   DOI   ScienceOn
14 Katamura Y, Aikata H, Takaki S, et al. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol 2009;44:492-502   DOI   ScienceOn
15 Tanaka A, Morimoto T, Yamaoka Y. Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein. Hepatogastroenterology 1996;43:637-643
16 Toya R, Murakami R, Baba Y, et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol 2007;84:266-271   DOI   ScienceOn
17 Barnett KT, Malafa MP. Complications of hepatic artery infusion: a review of 4580 reported cases. Int J Gastrointest Cancer 2001;30:147-160   DOI   ScienceOn
18 Kumada K, Ozawa K, Okamoto R, et al. Hepatic resection for advanced hepatocellular carcinoma with removal of portal vein tumor thrombi. Surgery 1990;108:821-827
19 Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397-401
20 Okada S. Transcatheter arterial embolization for advanced hepatocellular carcinoma: the controversy continues. Hepatology 1998;27:1743-1744   DOI   ScienceOn
21 Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008;113:995-1003   DOI   ScienceOn
22 Huang YJ, Hsu HC, Wang CY, et al. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009;73:1155-1163   DOI   ScienceOn
23 Nakagawa K, Yamashita H, Shiraishi K, et al. Radiation therapy for portal venous invasion by hepatocellular carcinoma. World J Gastroenterol 2005;11:7237-7241   DOI
24 Zeng ZC, Fan J, Tang ZY, et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005;61:432-443   DOI   ScienceOn
25 Kim JH, Choi EK, Ahn SD, et al. The role of radiotherapy in the treatment of portal vein thrombosis from advanced hepatocellular carcinoma. J Korean Soc Ther Radiol Oncol 2007;25:170-176
26 Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1):S5-S16   DOI
27 Zeng ZC, Fan J, Tang ZY, et al. Prognostic factors for patients with hepatocellular carcinoma with macroscopic portal vein or inferior vena cava tumor thrombi receiving external-beam radiation therapy. Cancer Sci 2008;99:2510-2517   DOI   ScienceOn
28 Korean Liver Cancer Study Group and National Cancer Center, Korea. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009;15:391-423   DOI   ScienceOn
29 Zirinsky K, Markisz JA, Rubenstein WA, et al. MR imaging of portal venous thrombosis: correlation with CT and sonography. AJR Am J Roentgenol 1988;150:283-288   DOI   ScienceOn
30 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108   DOI   ScienceOn
31 Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 2006;12:7561-7567
32 Takizawa D, Kakizaki S, Sohara N, et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci 2007;52:3290-3295   DOI   ScienceOn
33 Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005;100:1995-2004   DOI   ScienceOn